Abstract
Parkinson Disease (PD) is a common neurodegenerative disorder of intricate etiology, caused by progressive loss of aminergic neurons and accumulation of Lewy bodies. The predominant role of genetics in the etiology of the disease has emerged since the identification of the first pathogenetic mutation in SNCA (alpha-synuclein) gene, back in 1997. Mendelian parkinsonisms, a minority among all PD forms, have been deeply investigated, with 19 loci identified. More recently, genome wide association studies have provided convincing evidence that variants in some of these genes, as well as in other genes, may confer an increased risk for late onset, sporadic PD. Moreover, the finding that heterozygous mutations in the GBA gene (mutated in Gaucher disease) are among the strongest genetic susceptibility factors for PD, has widened the scenario of PD genetic background to enclose a number of genes previously associated to distinct disorders, such as genes causative of spinocerebellar ataxias, mitochondrial disorders and fragile X syndrome. At present, the genetic basis of PD defines a continuum from purely mendelian forms (such as those caused by autosomal recessive genes) to multifactorial inheritance, resulting from the variable interplay of many distinct genetic variants and environmental factors.
Keywords: Genetics, monogenic, multifactorial, Parkinson disease, parkinsonism, risk factor.
Current Molecular Medicine
Title:Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance
Volume: 14 Issue: 8
Author(s): S. Petrucci, F. Consoli and E.M. Valente
Affiliation:
Keywords: Genetics, monogenic, multifactorial, Parkinson disease, parkinsonism, risk factor.
Abstract: Parkinson Disease (PD) is a common neurodegenerative disorder of intricate etiology, caused by progressive loss of aminergic neurons and accumulation of Lewy bodies. The predominant role of genetics in the etiology of the disease has emerged since the identification of the first pathogenetic mutation in SNCA (alpha-synuclein) gene, back in 1997. Mendelian parkinsonisms, a minority among all PD forms, have been deeply investigated, with 19 loci identified. More recently, genome wide association studies have provided convincing evidence that variants in some of these genes, as well as in other genes, may confer an increased risk for late onset, sporadic PD. Moreover, the finding that heterozygous mutations in the GBA gene (mutated in Gaucher disease) are among the strongest genetic susceptibility factors for PD, has widened the scenario of PD genetic background to enclose a number of genes previously associated to distinct disorders, such as genes causative of spinocerebellar ataxias, mitochondrial disorders and fragile X syndrome. At present, the genetic basis of PD defines a continuum from purely mendelian forms (such as those caused by autosomal recessive genes) to multifactorial inheritance, resulting from the variable interplay of many distinct genetic variants and environmental factors.
Export Options
About this article
Cite this article as:
Petrucci S., Consoli F. and Valente E.M., Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance, Current Molecular Medicine 2014; 14 (8) . https://dx.doi.org/10.2174/1566524014666141010155509
| DOI https://dx.doi.org/10.2174/1566524014666141010155509 |
Print ISSN 1566-5240 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
From Molecular Mechanisms to Therapeutic Frontiers: The Versatile Roles of Chaperones in Medicine
Chaperones play critical roles in maintaining proteostasis by preventing protein misfolding and aggregation, which constitute central processes to the pathogenesis of numerous diseases such as neurodegeneration, cancer, and inflammatory disorders. This thematic issue will delve into the molecular mechanisms of chaperone function, their involvement in disease progression, and their potential ...read more
Metabolic Reprogramming and Molecular Pharmacology: Innovations in Drug Discovery and Therapeutic Targeting
Metabolic reprogramming is a hallmark of numerous diseases, including cancer, metabolic disorders, and neurodegeneration. Understanding the intricate cell signaling pathways, transduction pathways, and omics-based data is important for the development of novel pharmacological interventions. This special issue of Current Molecular Medicine will be devoted to the current advances in drug ...read more
Related Journals
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of KCa3.1 Channels in CNS Diseases: A Concise Review
CNS & Neurological Disorders - Drug Targets Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Oxidative Stress in Alzheimer Patients in Different Stages of the Disease
Current Medicinal Chemistry Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research Neuroinflammation in Prion Diseases: Concepts and Targets for Therapeutic Intervention
CNS & Neurological Disorders - Drug Targets The Small GTPase Activity of the ROC Domain from LRRK2, a Parkinsons Disease Related Protein
Protein & Peptide Letters Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular and Cellular Mechanisms for Alzheimers Disease:Understanding APP Metabolism
Current Molecular Medicine The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Current Topics in Medicinal Chemistry Ligand Docking and Structure-based Virtual Screening in Drug Discovery
Current Topics in Medicinal Chemistry Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy The Modulation of Beneficial and/or Harmful Effects of Free Oxygen Radicals in the Context of Molecular Mechanisms Regarding Drug – PART I
Current Topics in Medicinal Chemistry The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Editorial: Pharmaceutical Applications of Dendrimers
Current Pharmaceutical Design Protein Modification by β-N-Acetyl Glucosamine (O-GlcNAc) in Insulin Signaling and Insulin Resistance
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry





